Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Sable Confirms Extensive Outcropping Copper Mineralization within Multiple Structural Corridors at the Zorro Cu Target, Zorro Project, San Juan, Argentina
-
Emerita Announces Board and Management Transitions
-
Brady Corporation to Acquire Honeywell’s Productivity Solutions and Services Business, Expanding Portfolio with Data Capture and Workflow Solutions
-
Capital City Bank Group, Inc. Reports First Quarter 2026 Results
-
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development
-
Lahontan to Drill Historic Santa Fe Heap Leach Pads for Residual Gold & Silver
-
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
-
Aikido Security Launches Endpoint Protection for Developer Devices as Software Supply Chain Attacks Hit Unprecedented Scale
-
Ny interim ledelse i Wealth Fund Partners A/S
-
Signify share repurchase periodic update
-
TransAlta Appoints Mike Politeski as Chief Financial Officer and Grant Arnold as Chief Commercial Officer
-
SPARC AI Signs Second Ukrainian Drone Manufacturer, Expanding Distribution Footprint for GPS-Denied Software Platform
-
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to T
-
Helium Evolution Announces Completion of Grasslands 3D Seismic Program, Board Update and Strengthening Helium Market Outlook
-
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
-
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
-
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
-
Altus Group Announces Exemptive Relief from the Ontario Securities Commission in connection with its Substantial Issuer Bid
-
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
-
Blossom Gold Adds World-Class Exploration Expertise to its Senior Executive Team with the Appointment of Dr. John DeDecker as Vice President, Exploration
-
Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging
-
U.S. Energy Corp. Closes Expanded Senior Secured Debt Facility, Completing Phase 1 Capital Stack for Big Sky Carbon Hub; Formally Suspends Use of Equity Line of Credit
-
Vancity Climate Action Plan Targets Rising Climate and Affordability Pressures
-
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
-
Soleo Health Expands Rare Disease Capabilities With Launch of SoleoRare™, A Specialty Pharmacy Focused on Complex Patient Needs
-
Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
-
La Mancha Investments S. à r. l. to File Early Warning Report
-
Kustom Entertainment, Inc. Announces Reverse Stock Split
-
Bodor Laser Ranked No. 1 in Global Sales Volume for Seven Consecutive Years, Demonstrating Brand Strength Through Sustained Leadership
-
Share buy-back Program
-
YieldMax® ETFs Announces Distributions on MSST, NVIT, and TEST
-
Crypto News: Pepeto DeFi Project Announces More Than $9.3M Raised While Bitcoin Price Prediction Points To $150,000
-
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
-
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
-
B2Gold Announces Agreement to Sell its 70% Interest in Fingold Joint Venture to Agnico Eagle for US$325 million; B2Gold and Agnico Eagle to Enter into Nunavut Collaboration Agreement
-
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
-
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
-
BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB913 Million in 2026
-
Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan
-
Parsons Demand Response Technology to Optimize and Enable Los Angeles Department of Water & Power’s Operations and Strategic Plan
-
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
-
BOSS Zhipin's Sustained Share Repurchases Achieved Over RMB913 Million in 2026
-
Solera Introduces AI Engine, a Cloud-Native Intelligence Layer Powering Faster Innovation Across the Automotive Ecosystem
-
Followme Trading League Season 18 Begins Global Registration
-
CoatingSolution4U Wins Bronze at the 2026 Edison Awards in Materials Science
-
"Splendid Jiangsu" Shines in Hong Kong and Macao, Opening a New Chapter of Cultural Exchange and Industrial Integration
-
Heineken Holding N.V. reports transactions under its current share buyback programme
-
Heineken N.V. reports the progress of transactions under its current share buyback programme
-
Equinor ASA: Notice of annual general meeting 12 May 2026
-
Invitation: Q1 2026 Results Release and Conference Call - Wednesday, May 13th, 2026
